--- title: "This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday" description: "Top Wall Street analysts have initiated coverage on several stocks with bullish ratings. HC Wainwright's Andres Y. Maldonado rated Immunome Inc (NASDAQ:IMNM) as Buy with a price target of $40. Needham" type: "news" locale: "en" url: "https://longbridge.com/en/news/275766450.md" published_at: "2026-02-12T13:41:26.000Z" --- # This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday > Top Wall Street analysts have initiated coverage on several stocks with bullish ratings. HC Wainwright's Andres Y. Maldonado rated Immunome Inc (NASDAQ:IMNM) as Buy with a price target of $40. Needham's Kyle Peterson rated Sezzle Inc (NASDAQ:SEZL) as Buy with a target of $85. Rosenblatt's Barton Crockett rated USA TODAY Co Inc (NYSE:TDAY) as Buy with a target of $10. Analyst ratings reflect positive outlooks for these companies. Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. - HC Wainwright & Co. analyst Andres Y. Maldonado initiated coverage on **Immunome Inc** (NASDAQ:IMNM) with a Buy rating and announced a price target of $40. Immunome shares closed at $23.41 on Wednesday. See how other analysts view this stock. - Needham analyst Kyle Peterson initiated coverage on **Sezzle Inc** (NASDAQ:SEZL) with a Buy rating and announced a price target of $85. Sezzle shares closed at $62.86 on Wednesday. See how other analysts view this stock. - Rosenblatt analyst Barton Crockett initiated coverage on **USA TODAY Co Inc** (NYSE:TDAY) with a Buy rating and announced a price target of $10. USA Today shares closed at $6.17 on Wednesday. See how other analysts view this stock. Considering buying SEZL stock? Here’s what analysts think: Photo via Shutterstock ### Related Stocks - [SEZL.US - Sezzle](https://longbridge.com/en/quote/SEZL.US.md) - [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md) - [TDAY.US - USA TODAY](https://longbridge.com/en/quote/TDAY.US.md) - [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md) - [ARKF.US - ARK Fintech Innovation ETF](https://longbridge.com/en/quote/ARKF.US.md) - [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md) - [FINX.US - Global X Fintech](https://longbridge.com/en/quote/FINX.US.md) - [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Terns Pharmaceuticals, Inc.（纳斯达克股票代码：TERN）被券商给予 “适度买入” 的平均评级 | Terns Pharmaceuticals, Inc.（纳斯达克代码：TERN）获得了十三位分析师的 “适度买入” 平均评级。一位分析师将其评为卖出，十一位评为买入，一位评为强力买入。平均目标价为 58.11 美元。最近的报告显示，来自各个 | [Link](https://longbridge.com/en/news/276308345.md) | | Immunome 首席执行官赞扬第三阶段硬纤维瘤试验的成功、近期 FDA 新药申请计划以及 IM-1021 抗体药物偶联物的早期反应 | Immunome 首席执行官 Clay Siegall 在与 Guggenheim 的 Michael Schmidt 的对话中讨论了公司的肿瘤学管线和近期里程碑。他强调了 varegacestat 在纤维瘤的三期试验中的成功，并计划在未来 | [Link](https://longbridge.com/en/news/275963955.md) | | 冬海与谷歌深化合作以 AI 驱动创新 包括游戏 \| 联合早报网 | 冬海集团（Sea Limited）与谷歌深化合作，签署谅解备忘录，推动人工智能（AI）在游戏、代理商务和创新代理支付等核心业务的应用。双方旨在通过 AI 提升用户体验和运营效率，冬海的游戏业务 Garena 将利用谷歌的 AI 解决方案改善 | [Link](https://longbridge.com/en/news/276319833.md) | | 专家展望：9 位分析师眼中的 Krystal Biotech | Krystal Biotech（纳斯达克代码：KRYS）在过去三个月内获得了 9 位分析师的混合评级，12 个月的平均目标价为 324.44 美元，比之前的目标上涨了 27.34%。分析师们提高了他们的评级，其中 Chardan Capit | [Link](https://longbridge.com/en/news/276232530.md) | | GSA Capital Partners LLP 购买了 106,167 股 10x Genomics 的股票，代码为 $TXG | GSA Capital Partners LLP 在第三季度将其在 10x Genomics (NASDAQ:TXG) 的持股比例增加了 708.9%，收购了 106,167 股，使其总持股达到 121,144 股，价值 140 万美元。其 | [Link](https://longbridge.com/en/news/276216391.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.